|
125 Companies |
|
183 Products |
|
183 Products |
|
133 Mechanisms of Action |
|
1 Trial |
|
2306 News |
|
| «12345678910111213...4041» |
- | Trial completion, Trial primary completion date: DIMMISI: Efficacy Study of "Imaginative Distention", a Self Managed Tool to Cope With Fatigue,Insomnia and Stress in pw Insomnia and pw MS (clinicaltrials.gov) - Apr 4, 2017
P=N/A, N=144, Completed, Sponsor: Niguarda Hospital
Active, not recruiting --> Completed | Trial primary completion date: Oct 2016 --> Oct 2015
- Trial primary completion date: Exploratory Study to Assess Clinical Response to Gilenya® (Fingolimod) in Hispanics With RRMS (clinicaltrials.gov) - Mar 31, 2017
P=N/A, N=50, Active, not recruiting, Sponsor: University of Southern California
Active, not recruiting --> Completed | Trial primary completion date: Oct 2016 --> Oct 2015 Trial primary completion date: Apr 2014 --> Jul 2017
- | Trial completion, Enrollment change: Wahls Paleo Diet and Progressive Multiple Sclerosis (clinicaltrials.gov) - Mar 31, 2017
P=N/A, N=15, Completed, Sponsor: Terry L. Wahls
Trial primary completion date: Apr 2014 --> Jul 2017 Active, not recruiting --> Completed | N=45 --> 15
- | Trial completion, Enrollment change, Trial primary completion date: BCI: EEG-Based Brain-Computer Interface Project for Individuals With Amyotrophic Lateral Sclerosis (ALS) (clinicaltrials.gov) - Mar 30, 2017
P=N/A, N=102, Completed, Sponsor: Drexel University College of Medicine
Active, not recruiting --> Completed | N=45 --> 15 Recruiting --> Completed | N=150 --> 102 | Trial primary completion date: Dec 2020 --> Dec 2016
- | Trial completion: Clinical Trial on The Use of Autologous Bone Marrow Stem Cells in Amyotrophic Lateral Sclerosis (Extension CMN/ELA) (clinicaltrials.gov) - Mar 30, 2017
P1/2, N=63, Completed, Sponsor: Fundacion para la Formacion e Investigacion Sanitarias de la Region de Murcia
Recruiting --> Completed | N=150 --> 102 | Trial primary completion date: Dec 2020 --> Dec 2016 Active, not recruiting --> Completed
- | Arcalyst (rilonacept) / Regeneron, Kiniksa
Biomarker, Enrollment closed, Enrollment change: IL1-TRAP, Rilonacept, in Systemic Sclerosis (clinicaltrials.gov) - Mar 30, 2017
P1/2, N=19, Active, not recruiting, Sponsor: Boston University
Active, not recruiting --> Completed Recruiting --> Active, not recruiting | N=40 --> 19
- | Enrollment closed, Trial primary completion date: Vestibular Rehabilitation for Persons With Multiple Sclerosis: Who Benefits the Most? (MSVR3trial) (clinicaltrials.gov) - Mar 29, 2017
P=N/A, N=88, Active, not recruiting, Sponsor: University of Colorado, Denver
Recruiting --> Active, not recruiting | N=40 --> 19 Recruiting --> Active, not recruiting | Trial primary completion date: Mar 2016 --> Oct 2017
- | Trial completion, Phase classification, Trial primary completion date: CTSM: Effects of the Cross-Training in Patients With Multiple Sclerosis (clinicaltrials.gov) - Mar 29, 2017
P=N/A, N=45, Completed, Sponsor: Università degli Studi di Sassari
Recruiting --> Active, not recruiting | Trial primary completion date: Mar 2016 --> Oct 2017 Recruiting --> Completed | Phase classification: P1/2 --> PN/A | Trial primary completion date: Apr 2016 --> Mar 2017
- ||| Betaseron (IFN-β-1b) / Bayer
Trial completion, HEOR: BetaSleep: Investigating the Relationship Between Sleep, Quality of Life,Other Disorders and Therapies in MS Patients on Betaferon (clinicaltrials.gov) - Mar 27, 2017
P=N/A, N=138, Completed, Sponsor: Bayer
Recruiting --> Completed | Phase classification: P1/2 --> PN/A | Trial primary completion date: Apr 2016 --> Mar 2017 Active, not recruiting --> Completed
- | Trial completion: Safety of RG2077 in Patients With Multiple Sclerosis (clinicaltrials.gov) - Mar 26, 2017
P1, N=20, Completed, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Active, not recruiting --> Completed No longer recruiting --> Completed
- | Trial completion: Longitudinal Study of Outcomes Measures in ALS Trials (clinicaltrials.gov) - Mar 23, 2017
P=N/A, N=100, Completed, Sponsor: Massachusetts General Hospital
No longer recruiting --> Completed Active, not recruiting --> Completed
- | Myrbetriq (mirabegron) / Astellas
Trial primary completion date: Urodynamic and Clinical Efficacy of Mirabegron for Neurogenic Bladder Patients (clinicaltrials.gov) - Mar 22, 2017
P2/3, N=144, Enrolling by invitation, Sponsor: Lawson Health Research Institute
Active, not recruiting --> Completed Trial primary completion date: Jun 2017 --> Sep 2017
- | Xeomin (incobotulinumtoxinA) / Merz Pharma
Trial completion, Trial primary completion date: Safety of Xeomin for Lower Limb Spasticity in Multiple Sclerosis Patients (clinicaltrials.gov) - Mar 22, 2017
P4, N=27, Completed, Sponsor: Multiple Sclerosis Center of Northeastern New York
Trial primary completion date: Jun 2017 --> Sep 2017 Active, not recruiting --> Completed | Trial primary completion date: Dec 2016 --> Jan 2016
- ||||||| dalfampridine / Generic mfg.
Trial completion: A Safety and Efficacy Study of Oral Prolonged-Release Fampridine (BIIB041) in Japanese Participants With Multiple Sclerosis (clinicaltrials.gov) - Mar 21, 2017
P3, N=101, Completed, Sponsor: Biogen
Active, not recruiting --> Completed | Trial primary completion date: Dec 2016 --> Jan 2016 Active, not recruiting --> Completed
- |||| Rebif (human IFN-?-1a) / EMD Serono
Trial completion: PROCEED: Effectiveness of Rebif (clinicaltrials.gov) - Mar 10, 2017
P4, N=106, Completed, Sponsor: Merck KGaA
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | Sativex (nabiximols) / Jazz
Trial primary completion date: Safety and Efficacy on Spasticity Symptoms of a Cannabis Sativa Extract in Motor Neuron Disease (clinicaltrials.gov) - Mar 9, 2017
P2/3, N=60, Completed, Sponsor: Ospedale San Raffaele
Active, not recruiting --> Completed Trial primary completion date: Sep 2014 --> Dec 2015
- | Enrollment change: CSF: Cerebrospinal Fluid Repository (clinicaltrials.gov) - Mar 9, 2017
P=N/A, N=11, Completed, Sponsor: Drexel University College of Medicine
Trial primary completion date: Sep 2014 --> Dec 2015 N=200 --> 11
- | deferiprone / Generic mfg.
Trial completion, Enrollment change: SAFEFAIRALS: Focal Accumulation of Iron in Cerebral Regions in Early ALS (Amyotrophic Lateral Sclerosis) Patients (clinicaltrials.gov) - Mar 9, 2017
P2, N=23, Completed, Sponsor: University Hospital, Lille
N=200 --> 11 Active, not recruiting --> Completed | N=18 --> 23
- | ceftriaxone / Generic mfg.
Trial completion, Trial primary completion date: Compassionate Use of Ceftriaxone in Patients With Amyotrophic Lateral Sclerosis (ALS) (clinicaltrials.gov) - Mar 9, 2017
P=N/A, N=1, Completed, Sponsor: Drexel University College of Medicine
Active, not recruiting --> Completed | N=18 --> 23 Withdrawn --> Completed | Trial primary completion date: Apr 2008 --> Oct 2015
- | fingolimod / Generic mfg.
Trial primary completion date: Assessing Induction of Type II (M2) Monocytes/Macrophages in Patients Receiving Gilenya. (clinicaltrials.gov) - Mar 9, 2017
P=N/A, N=125, Active, not recruiting, Sponsor: University of Southern California
Withdrawn --> Completed | Trial primary completion date: Apr 2008 --> Oct 2015 Trial primary completion date: Sep 2016 --> Dec 2016
- | Trial primary completion date: Allogeneic Hematopoietic Cell Transplantation for Severe Systemic Sclerosis (clinicaltrials.gov) - Mar 8, 2017
P1/2, N=20, Recruiting, Sponsor: Fred Hutchinson Cancer Research Center
Trial primary completion date: Sep 2016 --> Dec 2016 Trial primary completion date: Sep 2017 --> Mar 2018
- | Trial completion, Trial primary completion date: PET Imaging in ALS Patients (clinicaltrials.gov) - Mar 7, 2017
P=N/A, N=36, Completed, Sponsor: Johns Hopkins University
Trial primary completion date: Sep 2017 --> Mar 2018 Recruiting --> Completed | Trial primary completion date: Aug 2015 --> Mar 2017
- | Phase classification: Caprylic Triglyceride for Treatment of Cognitive Impairments in Multiple Sclerosis (clinicaltrials.gov) - Mar 6, 2017
P=N/A, N=158, Recruiting, Sponsor: University of Miami
Recruiting --> Completed | Trial primary completion date: Aug 2015 --> Mar 2017 Phase classification: P2 --> P=N/A
- | Enrollment change: Effects of Meditation on Multiple Sclerosis and Peripheral Neuropathy (clinicaltrials.gov) - Mar 3, 2017
P=N/A, N=40, Completed, Sponsor: The Cleveland Clinic
Phase classification: P2 --> P=N/A N=50 --> 40
- ||| Trial completion, Trial primary completion date, Adverse events: Effect of Aerobic Exercise on Side Effects of Disease Modifying Therapy With Subcutaneous Interferon-b1b in Patients With Multiple Sclerosis (clinicaltrials.gov) - Mar 3, 2017
P=N/A, N=128, Completed, Sponsor: University of British Columbia
N=50 --> 40 Recruiting --> Completed | Trial primary completion date: Mar 2011 --> Jun 2012
- |||| Mayzent (siponimod) / Novartis
Trial completion, Enrollment change: Long-term Safety, Tolerability and Efficacy of BAF312 Given Orally in Patients With Relapsing-remitting Multiple Sclerosis (clinicaltrials.gov) - Mar 1, 2017
P2, N=185, Completed, Sponsor: Novartis Pharmaceuticals
Recruiting --> Completed | Trial primary completion date: Mar 2011 --> Jun 2012 Recruiting --> Completed | N=250 --> 185
- | Trial completion, Trial primary completion date: Assess Safety, Bio-distribution, Radiation Dosimetry and Optimize the Imaging Protocol of GEH120714 (18F) Injection in Healthy Volunteers and Participants With Relapsing and Remitting Multiple Sclerosis (rrMS). (clinicaltrials.gov) - Feb 24, 2017
P1, N=30, Completed, Sponsor: GE Healthcare
Recruiting --> Completed | N=250 --> 185 Active, not recruiting --> Completed | Trial primary completion date: Dec 2016 --> May 2016
- | Phase classification: MS-NANOSE: Applications of Nanotechnology in Multiple Sclerosis by Respiratory Samples (clinicaltrials.gov) - Feb 23, 2017
P=N/A, N=71, Completed, Sponsor: Carmel Medical Center
Active, not recruiting --> Completed | Trial primary completion date: Dec 2016 --> May 2016 Phase classification: P1 --> P=N/A
- | Phase classification: FlexToBa for People With Multiple Sclerosis (clinicaltrials.gov) - Feb 23, 2017
P=N/A, N=50, Completed, Sponsor: University of Illinois at Urbana-Champaign
Phase classification: P1 --> P=N/A Phase classification: P1 --> P=N/A
- || Trial primary completion date: Multi-Center Study Safety of Adipose Derived Mesenchymal Stem Cells for the Treatment of Multiple Sclerosis (clinicaltrials.gov) - Feb 15, 2017
P1, N=100, Recruiting, Sponsor: American CryoStem Corporation
Phase classification: P1 --> P=N/A Trial primary completion date: Nov 2016 --> Jan 2018
- |||| cyclophosphamide / Generic mfg.
Trial completion: Comparison of Therapeutic Regimens for Scleroderma Interstitial Lung Disease (The Scleroderma Lung Study II) (clinicaltrials.gov) - Feb 11, 2017
P2, N=142, Completed, Sponsor: Michael Roth
Trial primary completion date: Nov 2016 --> Jan 2018 Active, not recruiting --> Completed
- Enrollment open, Phase classification, Trial initiation date, Trial primary completion date: Task-oriented Circuit Training Combined With Cerebellar tDCS in Multiple Sclerosis Subjects (clinicaltrials.gov) - Feb 3, 2017
P=N/A, N=30, Recruiting, Sponsor: University Hospital of Ferrara
Active, not recruiting --> Completed Not yet recruiting --> Recruiting | Phase classification: P2 --> PN/A | Initiation date: May 2016 --> Feb 2017 | Trial primary completion date: Dec 2016 --> Jul 2017
- Enrollment closed, Enrollment change, Trial primary completion date: Effect of Vitamin D Replacement on Immune Function and Cognition in MS Patients (clinicaltrials.gov) - Feb 1, 2017
P=N/A, N=108, Active, not recruiting, Sponsor: American University of Beirut Medical Center
Not yet recruiting --> Recruiting | Phase classification: P2 --> PN/A | Initiation date: May 2016 --> Feb 2017 | Trial primary completion date: Dec 2016 --> Jul 2017 Recruiting --> Active, not recruiting | N=86 --> 108 | Trial primary completion date: Aug 2014 --> Jun 2017
- Ocrevus (ocrelizumab) / Roche, Biogen
Trial completion, P3 data: Assessment of Ocrelizumab (OCR) Treatment Effects on Functional Impairment of MS Patients Enrolled in the Phase III Orchestra Programme Using Multimodal Evoked Potentials (EP) and Highresolution Electroencephalography (EEG) (clinicaltrials.gov) - Feb 1, 2017
P3, N=16, Completed, Sponsor: University Hospital, Basel, Switzerland
Recruiting --> Active, not recruiting | N=86 --> 108 | Trial primary completion date: Aug 2014 --> Jun 2017 Active, not recruiting --> Completed
- | Avonex (recombinant IFN-β-1a) / Biogen
Trial completion, HEOR: SFERA: Tolerability and Quality of Life Study in Participants Who Switched to Avonex Pen (clinicaltrials.gov) - Jan 30, 2017
P=N/A, N=40, Completed, Sponsor: Biogen
Active, not recruiting --> Completed Active, not recruiting --> Completed
- Trial completion: Nocturnal PtcCO2 Monitoring in Patients With Amyotrophic Lateral Sclerosis (ALS) (clinicaltrials.gov) - Jan 26, 2017
P=N/A, N=66, Completed, Sponsor: Association Nationale pour les Traitements A Domicile, les Innovations et la Recherche
Active, not recruiting --> Completed Active, not recruiting --> Completed
- Trial termination: EMR200109_635: Vitamin D3 and the Stress-axis in MS (clinicaltrials.gov) - Jan 26, 2017
P2, N=54, Terminated, Sponsor: Academic MS Center Limburg
Active, not recruiting --> Completed Active, not recruiting --> Terminated; difficulties with inclusion
- | Betaseron (IFN-β-1b) / Bayer
Phase classification, HEOR: BetaSleep: Investigating the Relationship Between Sleep, Quality of Life,Other Disorders and Therapies in MS Patients on Betaferon (clinicaltrials.gov) - Jan 24, 2017
P=N/A, N=138, Active, not recruiting, Sponsor: Bayer
Active, not recruiting --> Terminated; difficulties with inclusion Phase classification: P4 --> P=N/A
- Trial completion: Respiratory Function and Walking Capacity in Multiple Sclerosis (clinicaltrials.gov) - Jan 18, 2017
P=N/A, N=50, Completed, Sponsor: Region Örebro County
Phase classification: P4 --> P=N/A Active, not recruiting --> Completed
- Biomarker, Trial primary completion date: Potential EEG Biomarkers and Antiepileptogenic Strategies for Epilepsy in TSC (clinicaltrials.gov) - Jan 10, 2017
P=N/A, N=40, Active, not recruiting, Sponsor: University of Alabama at Birmingham
Active, not recruiting --> Completed Trial primary completion date: Dec 2016 --> Dec 2017
- |||| Tcelna (imilecleucel-T) / Acer Therap, EMD Serono
Trial completion: Study of Tcelna (Imilecleucel-T) in Secondary Progressive Multiple Sclerosis (clinicaltrials.gov) - Jan 10, 2017
P2, N=183, Completed, Sponsor: Opexa Therapeutics, Inc.
Trial primary completion date: Dec 2016 --> Dec 2017 Active, not recruiting --> Completed
- | oxcarbazepine / Generic mfg.
Enrollment change: PROXIMUS: Protective Role of Oxcarbazepine in Multiple Sclerosis (clinicaltrials.gov) - Jan 10, 2017
P2a, N=30, Recruiting, Sponsor: Queen Mary University of London
Active, not recruiting --> Completed N=60 --> 30
- ||||||| Tysabri (natalizumab) / Biogen, Royalty
Trial completion: Safety and Efficacy of Natalizumab in the Treatment of Multiple Sclerosis (clinicaltrials.gov) - Jan 8, 2017
P3, N=900, Completed, Sponsor: Biogen
N=60 --> 30 No longer recruiting --> Completed
- Trial completion, Enrollment change, Trial primary completion date: Amyotrophic Lateral Sclerosis (ALS) Tissue Donation Program (clinicaltrials.gov) - Jan 6, 2017
P=N/A, N=205, Completed, Sponsor: Drexel University College of Medicine
No longer recruiting --> Completed Recruiting --> Completed | N=300 --> 205 | Trial primary completion date: Dec 2025 --> Nov 2016
- Trial completion, Enrollment change, Trial primary completion date: Non-Invasive Measurement of Gastrointestinal (GI) Motility in Patients With Amyotrophic Lateral Sclerosis (ALS) (clinicaltrials.gov) - Jan 6, 2017
P=N/A, N=41, Completed, Sponsor: Christine Barr
Recruiting --> Completed | N=300 --> 205 | Trial primary completion date: Dec 2025 --> Nov 2016 Recruiting --> Completed | N=60 --> 41 | Trial primary completion date: Aug 2018 --> Nov 2016
- Trial primary completion date: Multidimensional Assessment of Fatigue in Multiple Sclerosis- Observational Study - Ticino (clinicaltrials.gov) - Dec 30, 2016
P=N/A, N=100, Recruiting, Sponsor: Claudio Gobbi
Recruiting --> Completed | N=60 --> 41 | Trial primary completion date: Aug 2018 --> Nov 2016 Trial primary completion date: Dec 2016 --> Dec 2017
- Trial primary completion date: SOCOG-MS: Study of Social Cognition by Morphological and Functional Imaging in Multiple Sclerosis Patients (clinicaltrials.gov) - Dec 23, 2016
P=N/A, N=35, Recruiting, Sponsor: University Hospital, Bordeaux
Trial primary completion date: Dec 2016 --> Dec 2017 Trial primary completion date: Nov 2016 --> Apr 2017
- ||| Betaseron (IFN-β-1b) / Bayer
Trial completion, Adherence: BETAEVAL Global - The New BETACONNECT Auto-injector : Adherence and EVALuation of Multiple Sclerosis Patients Treated With Betaferon (clinicaltrials.gov) - Dec 22, 2016
P=N/A, N=479, Completed, Sponsor: Bayer
Trial primary completion date: Nov 2016 --> Apr 2017 Active, not recruiting --> Completed
- vatelizumab (GBR 500) / Glenmark
Trial primary completion date: Efficacy and Safety of Vatelizumab in Patients Who Completed Treatment in Study DRI13839 (clinicaltrials.gov) - Dec 21, 2016
P2, N=62, Terminated, Sponsor: Genzyme, a Sanofi Company
Active, not recruiting --> Completed Trial primary completion date: Oct 2015 --> Apr 2016
- vatelizumab (GBR 500) / Glenmark
Trial primary completion date: Efficacy and Safety of Vatelizumab in Patients With Relapsing-Remitting Multiple Sclerosis (clinicaltrials.gov) - Dec 21, 2016
P2a/2b, N=112, Terminated, Sponsor: Genzyme, a Sanofi Company
Trial primary completion date: Oct 2015 --> Apr 2016 Trial primary completion date: Nov 2015 --> Apr 2016